Skip to content
MarketScale
‹ Back to IndustriesHealthcare

A Digital Health Solution for Chronic Pain Sufferers

For chronic pain sufferers, an increase in pain levels is typically associated with higher stress and anxiety levels. But in a time when a terrible pandemic has wreaked havoc across the globe, everyone’s anxiety levels are escalating, particularly for those with chronic pain, intensifying pain beyond usual levels. And because there is no acute…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
A Digital Health Solution for Chronic Pain Sufferers

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

For chronic pain sufferers, an increase in pain levels is typically associated with higher stress and anxiety levels. But in a time when a terrible pandemic has wreaked havoc across the globe, everyone’s anxiety levels are escalating, particularly for those with chronic pain, intensifying pain beyond usual levels. And because there is no acute illness, pain management in a primary care or outpatient setting may not be considered a priority for physicians during a global health crisis.

Thus, patient anxiety and pain levels rise further as they worry about not being able to see their doctor for medication refills, treatments, or basic follow-ups. Making matters worse, the closing of businesses providing massage, acupuncture, exercise and counseling services that aid in pain relief has essentially demolished the alternate pathways these sufferers can traverse to control their pain. Further, depression and anxiety are the top symptoms of chronic pain, and social distancing measures have undoubtedly resulted in an overwhelming sense of social isolation, deepening feelings of unhappiness and hopelessness for these patients.

Sadly, one in three Americans suffers from chronic pain—that’s 100 million people in this country alone. Because pain measurement is subjective, often taking three to six months to diagnose, the condition is often overlooked by the healthcare community; and even when diagnosed, the treatment most strongly encouraged over the past 25 years has been opioids. But as the opioid crisis swept the U.S., a search for alternatives to pain management became a national crusade.

On this MarketScale videostream, Celine Tien, the Founder of Flowly, joins MarketScale’s Daniel Litwin, the Voice of B2B, to discuss the launch of Flowly and the role of telehealth and telemedicine during the COVID-19 crisis and beyond. Flowly is a data-focused bio-feedback mobile app for chronic pain and anxiety sufferers, enabling users to explore interactive VR- and phone-enabled experiences in order to teach them how to regulate their nervous systems through relaxation training. Flowly also keeps track of a user’s progress while allowing them to share it all with a supportive community.

“We saw a survey with the U.S. Pain Foundation where people with chronic pain and chronic illnesses who are also immunosuppressed are particularly vulnerable to viruses like COVID-19. They’re getting even less access to health care than they did before.” Tien explained. “Initially we had wanted to launch Flowly later this year, but when COVID hit—I would say at the peak in March—we had such an inundation of messages and people reaching out to us asking if they could access our data immediately because people were so in need of something that they could remotely access at home to help them manage their pain.”

Bringing thought leadership to your day, MarketScale hosts industry experts so that you stay informed of the newest trends, events and beyond in B2B. And for the latest thought leadership, news and event coverage across Healthcare and other industry sectors, be sure to check out our Industry pages.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512